Clinical Trial

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-01-14; most recent amendment 2026-03-06.
Status change: Not Yet Recruiting → Recruiting 2021-07-20
Trial Details
NCT Number NCT04712851
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Enrollment 25 participants
Start Date 2021-06-30
Primary Completion 2027-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10